-
Mashup Score: 19HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405 - 1 month(s) ago
PURPOSE The phase III Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial found no difference in overall survival (OS) in patients with metastatic colorectal cancer receiving first-line chemotherapy in combination with either bevacizumab or cetuximab. We investigated the potential prognostic and predictive value of HER2 amplification and gene expression using next-generation sequencing (NGS) and NanoString data. PATIENTS AND METHODS Primary tumor DNA from 559 patients was profiled for HER2 amplification by NGS (FoundationOne CDx). Tumor tissue from 925 patients was tested for NanoString gene expression using an 800-gene panel. OS and progression-free survival (PFS) were the time-to-event end points. RESULTS High HER2 expression (dichotomized at median) was associated with longer PFS (11.6 v 10 months, P = .012) and OS (32 v 25.3 months, P = .033), independent of treatment. An OS benefit for cetuximab versus bevacizumab was observed in the high HER2 expression group (P = .02), whereas
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 13Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma - 1 month(s) ago
PURPOSE There are limited data on antiviral treatment utilization and its impact on long-term outcomes of hepatitis B virus (HBV)– and hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC) after hepatic resection. We aimed to determine the utilization and impact of antivirals in HBV- and HCV-related HCC. METHODS This cohort study included 1,906 participants (1,054 HBV-related HCC and 852 HCV-related HCC) from 12 international sites. All participants had HBV- or HCV-related HCC and underwent curative surgical resection. The primary outcome was the utilization of antiviral therapy, and the secondary outcome was long-term overall survival (OS). RESULTS The mean (±standard deviation [SD]) age was 62.1 (±11.3) years, 74% were male, and 84% were Asian. A total of 47% of the total cohort received antiviral therapy during a mean (±SD) follow-up of 5.0 (±4.3) years. The overall antiviral utilization for participants with HBV-related HCC was 57% and declined over time, from 65% before 2
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 12Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial - 1 month(s) ago
Nature Medicine – In the phase 2 RENOBATE trial, the combination of regorafenib and nivolumab as first-line treatment for unresectable hepatocellular carcinoma exhibited a safe profile and met the…
Source: www.nature.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 3Precision treatment in advanced hepatocellular carcinoma - 1 month(s) ago
The precision treatment of hepatocellular carcinoma (HCC) has progressed significantly in recent decades. Yang et al. review key aspects of precision treatment in HCC, including therapeutic biomarkers, molecular classifications, and the heterogeneity of the tumor microenvironment. They also discuss future research directions to further advance this field.
Source: www.cell.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 2Fola May: New Guardant Health blood-based colorectal cancer screening test - OncoDaily - 1 month(s) ago
Fola May: New Guardant Health blood-based colorectal cancer screening test / blood-based colorectal cancer screening test, cancer, cancer detection, cancer
Source: oncodaily.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 15Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer - 1 month(s) ago
Nature Medicine – In an exploratory preplanned biomarker analysis of the phase 3 PARADIGM trial, a lack of resistance gene alterations in baseline circulating tumor DNA (negative hyperselection)…
Source: www.nature.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 94Bitcoin Pre-Halving Retrace “Danger Zone” Is Here - 1 month(s) ago
📈 Sign up to my newsletter for FREE: https://newsletter.rektcapital.co/#/portal/signup/free🎯 Join my FREE 5-day Technical Analysis email course: https://cr…
Source: www.youtube.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 15HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405 - 2 month(s) ago
PURPOSE The phase III Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial found no difference in overall survival (OS) in patients with metastatic colorectal cancer receiving first-line chemotherapy in combination with either bevacizumab or cetuximab. We investigated the potential prognostic and predictive value of HER2 amplification and gene expression using next-generation sequencing (NGS) and NanoString data. PATIENTS AND METHODS Primary tumor DNA from 559 patients was profiled for HER2 amplification by NGS (FoundationOne CDx). Tumor tissue from 925 patients was tested for NanoString gene expression using an 800-gene panel. OS and progression-free survival (PFS) were the time-to-event end points. RESULTS High HER2 expression (dichotomized at median) was associated with longer PFS (11.6 v 10 months, P = .012) and OS (32 v 25.3 months, P = .033), independent of treatment. An OS benefit for cetuximab versus bevacizumab was observed in the high HER2 expression group (P = .02), whereas
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 15HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405 - 2 month(s) ago
PURPOSE The phase III Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial found no difference in overall survival (OS) in patients with metastatic colorectal cancer receiving first-line chemotherapy in combination with either bevacizumab or cetuximab. We investigated the potential prognostic and predictive value of HER2 amplification and gene expression using next-generation sequencing (NGS) and NanoString data. PATIENTS AND METHODS Primary tumor DNA from 559 patients was profiled for HER2 amplification by NGS (FoundationOne CDx). Tumor tissue from 925 patients was tested for NanoString gene expression using an 800-gene panel. OS and progression-free survival (PFS) were the time-to-event end points. RESULTS High HER2 expression (dichotomized at median) was associated with longer PFS (11.6 v 10 months, P = .012) and OS (32 v 25.3 months, P = .033), independent of treatment. An OS benefit for cetuximab versus bevacizumab was observed in the high HER2 expression group (P = .02), whereas
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 12Trastuzumab plus Pertuzumab for HER2-amplified Advanced Colorectal Cancer: Results from the Drug Rediscovery Protocol (DRUP) - 2 month(s) ago
In 2-5% of patients with colorectal cancer (CRC), human epidermal growth factor 2 (HER2) is amplified or overexpressed. Despite prior evidence that an…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
RT @ArndtVogel: HER2 Gene Expression Levels Are Predictive and Prognostic in CRC @JCO_ASCO https://t.co/VylVpDnbMa 🔎CALGB/SWOG 80405 👉Prog…